Quick Answer
LIGAND PHARMACEUTICALS INC reported Research And Development Expense of $81.18 million for the year ending 2025.
- LIGAND PHARMACEUTICALS INC showed an increase of +278.9% in Research And Development Expense from 2024 to 2025.
- This data is from LIGAND PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), LIGAND PHARMACEUTICALS INC's Research And Development Expense has grown by 103.6%.
- Historical annual values: Fiscal year 2025: $81.18 million | Fiscal year 2024: $21.43 million | Fiscal year 2023: $24.54 million | Fiscal year 2022: $36.08 million | Fiscal year 2021: $32.11 million | Fiscal year 2020: $40.50 million | Fiscal year 2019: $55.91 million | Fiscal year 2018: $27.86 million | Fiscal year 2017: $26.89 million | Fiscal year 2016: $21.22 million | Fiscal year 2015: $11.01 million | Fiscal year 2014: $9.75 million | Fiscal year 2013: $9.27 million | Fiscal year 2012: $10.79 million | Fiscal year 2011: $10.29 million | Fiscal year 2010: $22.07 million | Fiscal year 2009: $39.87 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: